AASK COHORT STUDY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The African American Study of Kidney Disease and Hypertension (AASK) Cohort Study is a prospective, observational study that will be a development from the AASK clinical trial. The AASK trial was a randomized trial that tested the effect on kidney function (glomerular filtration rate and clinical kidney events) of 3 different medications used as first line antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control (usual control and more aggressive control). Of the 1,094 participants randomized into the AASK trial 4-6 years ago, we anticipate that 650-750 individuals who have not reached end-stage renal disease (ESRD) will enroll in the AASK Cohort study. In addition, those individuals who reached ESRD during the AASK trial will be asked to participate for one visit for collection of deoxyribonucleic acid (DNA). The AASK Cohort participants will have 2 data collection visits each year and up to 4 additional visits for blood pressure management. Exposures to be monitored include environmental, genetic, physiologic, and socio-economic factors. The primary renal outcome will be a clinical outcome defined by doubling of serum creatinine, attainment of ESRD, or death.